Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2026-02-08 @ 5:44 PM
Study NCT ID:
NCT02836795
Status:
COMPLETED
Last Update Posted:
2025-06-08
First Post:
2016-07-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 35}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-04', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-10', 'completionDateStruct': {'date': '2018-12-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-06-05', 'studyFirstSubmitDate': '2016-07-11', 'studyFirstSubmitQcDate': '2016-07-18', 'lastUpdatePostDateStruct': {'date': '2025-06-08', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-07-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'correlation analysis of PD-L1 expression of tumor and ORR', 'timeFrame': '3 years'}, {'measure': 'correlation analysis of PD-L1 expression of tumor and DOR', 'timeFrame': '3 years'}, {'measure': 'correlation analysis of PD-L1 expression of tumor and DCR', 'timeFrame': '3 years'}, {'measure': 'correlation analysis of PD-L1 expression of tumor and TTR', 'timeFrame': '3 years'}, {'measure': 'correlation analysis of PD-L1 expression of tumor and PFS', 'timeFrame': '3 years'}, {'measure': 'correlation analysis of PD-L1 expression of tumor and OS', 'timeFrame': '3 years'}], 'primaryOutcomes': [{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '1.5 years'}], 'secondaryOutcomes': [{'measure': 'PD-1 receptor occupancy of blood', 'timeFrame': '1.5 years'}, {'measure': 'Objective Response Rate (ORR) by irRC and RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Duration of Response (DOR) by irRC and RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Disease Control Rate (DCR) by irRC and RECIST 1.1', 'timeFrame': '3 year'}, {'measure': 'Time to response (TTR) by irRC and RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Progression-free survival(PFS) by irRC and RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Overall survival (OS) by irRC and RECIST 1.1', 'timeFrame': '3 years'}, {'measure': 'Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)', 'timeFrame': '1.5 years'}, {'measure': 'Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 't1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}, {'measure': 'Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb', 'timeFrame': '1.5 years'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['anti-PD-1 monoclonal antibody', 'advanced solid tumors', 'safety'], 'conditions': ['Melanoma', 'Urological Cancer']}, 'referencesModule': {'references': [{'pmid': '26947879', 'type': 'BACKGROUND', 'citation': 'Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010.'}, {'pmid': '26115796', 'type': 'BACKGROUND', 'citation': "Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23."}, {'pmid': '30642373', 'type': 'DERIVED', 'citation': 'Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019 Jan 14;12(1):7. doi: 10.1186/s13045-018-0693-2.'}]}, 'descriptionModule': {'briefSummary': 'This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion to investigate tolerability and efficacy.', 'detailedDescription': 'This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced solid tumor (melanoma or urological cancers) who have failed in previous routine systemic treatment. The study will be conducted in 2 parts: dose escalation and cohort expansion. In the first part, nine patients are injected with different dosage of the humanized anti-PD-1 antibody (1mg/kg or 3mg/kg or 10mg/mg, three patients in one group ) once and observed carefully in the following 4 weeks. If no dose-limiting toxicity (DLT) occurs, then they are injected every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to confirm DLT, maximum tolerated dose (MTD) and recommended dose (RD). In the second part, 6-12 patients are enrolled in each dosage group and injected with the humanized anti-PD-1 antibody every 2 weeks until disease progresses or unacceptable toxicity occurs. This part is to further analyze safety and efficacy of the humanized anti-PD-1 antibody.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male and Female aged 18 to 70 years are eligible;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Histologic diagnosis of unresectable melanoma or urological cancer. Have failed at least 1 prior routine regimen for metastatic disease, or failed to tolerate the toxicity, or lack of any routine regimens.\n* Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);\n* At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \\>=20mm, spiral CT scan \\>=10mm, no prior radiation to measurable lesions) Predicted survival \\>=6 months;\n* Brain or meningeal metastases must be disposed with surgery or radiation, and be stable clinically for at least 8 weeks (prior systemic steroids was allowed, but concurrent administration of systemic steroids with the study drug is excluded).\n* Screening laboratory values must meet the following criteria（within past 14 days）:\n\nhemoglobin ≥ 9.0 g/dL neutrophils ≥ 1500 cells/ µL platelets ≥ 100 x 10\\^3/ µL total bilirubin ≤ 1.5 x upper limit of normal (ULN) aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis serum creatinine ≤1╳ULN，creatinine clearance \\>50ml/min (Cockcroft-Gault equation)\n\n* Without systemic steroids within past 4 weeks\n* Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.\n* Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Ab or its components.\n* Prior treatment with mAb within past 3 months (locally administration excluded)\n* Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;\n* Pregnant or nursing\n* Abnormal Blood coagulation\n* Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (\\>500IU/ml)\n* History with pulmonary tuberculosis;\n* Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism.\n* Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure \\> class II NYHA, heart block \\>II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm).\n* Evidence with CNS disease.\n* Prior treatment with bone marrow stimulating factors，such as CSF (colony stimulating factor), EPO (erythropoietin), within past 1 weeks\n* Prior live vaccine therapy within past 4 weeks.\n* Prior major surgery within past 4 weeks (diagnostic surgery excluded).\n* Psychiatric medicines abuse without withdrawal, or history of psychiatric illness.\n* Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix.\n* Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events."}, 'identificationModule': {'nctId': 'NCT02836795', 'briefTitle': 'Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors', 'organization': {'class': 'OTHER', 'fullName': 'Shanghai Junshi Bioscience Co., Ltd.'}, 'officialTitle': 'A Phase I, Open Label, Single Center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors', 'orgStudyIdInfo': {'id': 'Junshi-JS001-BJZL-I'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'humanized anti-PD-1 monoclonal antibody Toripalimab', 'description': 'humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.', 'interventionNames': ['Biological: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)']}], 'interventions': [{'name': 'humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)', 'type': 'BIOLOGICAL', 'otherNames': ['JS001, TAB001'], 'description': 'humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.', 'armGroupLabels': ['humanized anti-PD-1 monoclonal antibody Toripalimab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100142', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Beijing Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}], 'overallOfficials': [{'name': 'Jun Guo, Phd MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Peking University Cancer Hospital & Institute'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shanghai Junshi Bioscience Co., Ltd.', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}